Literature DB >> 21617715

Interaction effect between the receptor for advanced glycation end products (RAGE) and high-mobility group box-1 (HMGB-1) for the migration of a squamous cell carcinoma cell line.

June Choi1, Min Koo Lee, Kyoung Ho Oh, Yeon Soo Kim, Han Young Choi, Seung Kuk Baek, Kwang Yoon Jung, Jeong-Soo Woo, Seung Hoon Lee, Soon Young Kwon.   

Abstract

AIMS AND
BACKGROUND: The receptor for advanced glycation end products (RAGE) is a multiligand cell surface receptor of the immunoglobulin superfamily and a newly recognized invasion-related gene. High mobility group box-1 (HMGB-1) is a 30-kD protein binding to RAGE and acting as a transcription-factor-like protein that regulates the expression of several genes. In this study, the interaction effect between RAGE and HMGB-1 on the migration of SCC7 cells was investigated along with the inhibitory effect of the drug nifedipine on this interaction effect. METHODS AND STUDY
DESIGN: Ten surgical specimens from patients with squamous cell carcinoma (SCC) of the head and neck and a SCC7 cell line were stained using immunohistochemical and immunocytochemical methods. Reverse transcriptase-polymerase chain reaction (RT-PCR) was used to detect RAGE expression in SCC7 cells; Western blot analysis was used to detect HMGB-1 expression in SCC7 cells. An in vitro migration assay (Boyden chamber migration assay) was used for evaluating the interaction effect between RAGE and HMGB-1 on the migration of SCC7 cells. HMGB-1 and various concentrations of nifedipine were tested for their effect on SCC7 cell migration with in vitro migration assays. RESULTS AND
CONCLUSIONS: RAGE and HMGB-1 were expressed in almost all human head and neck SCC tissues and in SCC7 cells as detected by immunostaining. The migration assay showed that the interaction between RAGE and HMGB-1 increased SCC7 migration activity depending on the level of HMGB-1, and nifedipine inhibited the interaction effect between RAGE and HMGB-1 on SCC7 cells in a dose-dependent manner. The interaction between RAGE and HMGB-1 could be closely associated with metastasis of SCC of the head and neck. Nifedipine may have an inhibitory effect on tumor metastasis.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21617715     DOI: 10.1177/030089161109700211

Source DB:  PubMed          Journal:  Tumori        ISSN: 0300-8916


  6 in total

1.  Expression of aldehyde dehydrogenase family 1 member A1 and high mobility group box 1 in oropharyngeal squamous cell carcinoma in association with survival time.

Authors:  Xu Qian; Annekatrin Coordes; Andreas M Kaufmann; Andreas E Albers
Journal:  Oncol Lett       Date:  2016-09-07       Impact factor: 2.967

2.  Malondialdehyde-derived epitopes in human skin result from acute exposure to solar UV and occur in nonmelanoma skin cancer tissue.

Authors:  Joshua D Williams; Yira Bermudez; Sophia L Park; Steven P Stratton; Koji Uchida; Craig A Hurst; Georg T Wondrak
Journal:  J Photochem Photobiol B       Date:  2014-02-12       Impact factor: 6.252

3.  The activation of HMGB1 as a progression factor on inflammation response in normal human bronchial epithelial cells through RAGE/JNK/NF-κB pathway.

Authors:  Xiaojin Wu; Yanyan Mi; Hui Yang; Ankang Hu; Qingguo Zhang; Chunli Shang
Journal:  Mol Cell Biochem       Date:  2013-05-26       Impact factor: 3.396

4.  Concurrent alterations of RAGE, RECK, and MMP9 protein expression are relevant to Epstein-Barr virus infection, metastasis, and survival in nasopharyngeal carcinoma.

Authors:  Dong-Ni Zhou; Yan-Fei Deng; Rong-Hua Li; Ping Yin; Chun-Sheng Ye
Journal:  Int J Clin Exp Pathol       Date:  2014-05-15

5.  Nisin, an apoptogenic bacteriocin and food preservative, attenuates HNSCC tumorigenesis via CHAC1.

Authors:  Nam E Joo; Kathryn Ritchie; Pachiyappan Kamarajan; Di Miao; Yvonne L Kapila
Journal:  Cancer Med       Date:  2012-10-02       Impact factor: 4.452

6.  The anti-tumor effects of evodiamine on oral squamous cell carcinoma (OSCC) through regulating advanced glycation end products (AGE) / receptor for advanced glycation end products (RAGE) pathway.

Authors:  Liuyang Ren; Ying Lou; Mingyu Sun
Journal:  Bioengineered       Date:  2021-12       Impact factor: 3.269

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.